Newsroom
23 press releases and 54 media coverage stories
IBTV: Advanced Therapies Week 2025
IBTV
Josh Ludwig - Global Commercial Director at ScaleReady talks to IBTV about G-Rex®, open collaboration and ScaleReady's current projects at Phacilitate's - Advanced Therapies Week at the Kay Bailey Hutchison Convention Center, Dallas, Texas, 20 – 23 January 2025.
Read the article : IBTV: Advanced Therapies Week 2025Share: IBTV: Advanced Therapies Week 2025
Pharma’s Almanac: How is the pharmaceutical industry integrating innovations from adjacent industries
Pharma's Almanac
Josh Ludwig of ScaleReady unpacks how the pharmaceutical industry is tapping into innovations from adjacent sectors to revolutionize drug development and manufacturing. From automation and AI-driven analytics to advanced bioprocessing techniques, discover how lessons from tech, automotive, and other industries are accelerating efficiency, scalability, and accessibility in pharma. Learn why integrating outside expertise isn’t just a trend—it’s the key to driving the next wave of breakthroughs in medicine.
Read the article : Pharma’s Almanac: How is the pharmaceutical industry integrating innovations from adjacent industriesShare: Pharma’s Almanac: How is the pharmaceutical industry integrating innovations from adjacent industries
BioXconomy: The sustainability series: Reflect, rethink, and reform
BioXconomy
In the latest installment of The Sustainability Series, industry leaders explore why sustainability in biotech goes beyond environmental responsibility—it’s about long-term viability, ethical production, and global health equity. Discover how companies are reflecting on current practices, rethinking supply chains, and reforming strategies to create a more resilient and responsible future for life sciences. Learn why a shift toward sustainability isn’t just a choice—it’s an imperative for innovation and impact.
Read the article : BioXconomy: The sustainability series: Reflect, rethink, and reformShare: BioXconomy: The sustainability series: Reflect, rethink, and reform
Medicine Maker: Get into My Car(-T)
The Medicine Maker
In this deep dive into cutting-edge biotech, Wilson Wolf explores the transformative potential of scalable cell manufacturing. Discover how innovative technologies, like the G-Rex® platform, are redefining efficiency, overcoming production bottlenecks, and paving the way for greater access to life-saving cell therapies. Learn how advancements in automation, standardization, and cost-effective solutions are accelerating the future of cell therapy—bridging the gap between groundbreaking science and real-world patient impact.
Read the article : Medicine Maker: Get into My Car(-T)Share: Medicine Maker: Get into My Car(-T)
Drug Discovery World: Looking ahead for cell and gene therapy
Drug Discovery World
The CGT sector is making significant strides, highlighted by the FDA approval of the first CRISPR therapeutic. Experts, including Josh Ludwig, Global Director, Commercial Operations, ScaleReady, predict continued growth and innovation in 2024 and beyond. Key challenges include manufacturing capacity, standardization, and delivery systems. However, advancements in technology and partnerships between developers and manufacturers offer promising solutions.
Read the article : Drug Discovery World: Looking ahead for cell and gene therapyShare: Drug Discovery World: Looking ahead for cell and gene therapy
MaxCyte: MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex® Grant Program
MaxCyte
MaxCyte and ScaleReady have partnered for the G-Rex® Grant Program, which aims to accelerate cell and gene therapy development. The program offers resources, tools, and expertise to recipients. MaxCyte's electroporation technology and ScaleReady's manufacturing solutions are key components of the program. The goal is to reduce barriers to entry for CGT companies and expedite the development of life-saving therapies.
Read the article : MaxCyte: MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex® Grant ProgramShare: MaxCyte: MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex® Grant Program
BioProcess International: ScaleReady awards first G-Rex® Grant to Stanford professor
BioProcess International
Bio-Techne, Wilson Wolf, and CellReady awarded a $300,000 G-Rex® Grant to Stanford Medicine's LCGM for CAR-T cell therapy manufacturing. The grant is part of a $20 million initiative to support CGT development. Eligible recipients receive supplies, support, and discounts. Stanford Medicine LCGM plans to use the grant for a Phase I trial and potency testing. Feldman from Stanford Medicine LCGM expressed the grant's importance for future clinical trials. Wilson from Wilson Wolf praised Stanford University's reputation for innovation.
Read the article : BioProcess International: ScaleReady awards first G-Rex® Grant to Stanford professorShare: BioProcess International: ScaleReady awards first G-Rex® Grant to Stanford professor
BioProcess International Podcast: Sustainability is about health equity, says ScaleReady and Germfree
BioProcess International
In this episode of Voices of Biotech podcast, ScaleReady's Josh Ludwig and Germfree's Carol Houts dive into the critical need for a more sustainable and standardized manufacturing model to improve access to life-saving therapies. Discover how decentralized manufacturing can revolutionize the industry, addressing challenges like talent shortages and drug supply issues. Learn why sustainability isn't just about the environment but also about patient care and health equity.
Read the article : BioProcess International Podcast: Sustainability is about health equity, says ScaleReady and GermfreeShare: BioProcess International Podcast: Sustainability is about health equity, says ScaleReady and Germfree
Genetic Engineering & Biotechnology News: Automation and Know-How Vital for Cell and Gene Therapy Scaleup
GEN
Cell and gene therapy companies struggle to scale up production. ScaleReady’s Global Director Josh Ludwig argues they lack essential manufacturing expertise. Unlike industries like automotive and medical devices, CGT firms often ignore proven methods. To succeed, they must hire manufacturing experts and effectively use automation.
Read the article : Genetic Engineering & Biotechnology News: Automation and Know-How Vital for Cell and Gene Therapy ScaleupShare: Genetic Engineering & Biotechnology News: Automation and Know-How Vital for Cell and Gene Therapy Scaleup
Drug Discovery World: Event highlights in 2024 so far
Drug Discovery World
ISCT 2024 showcased the latest in cell and gene therapy (CGT). A key focus was on industry sustainability. Josh Ludwig from ScaleReady emphasized the need for operational efficiency over simply expanding space. Optimizing processes like inventory management is crucial for reducing costs and environmental impact.
Read the article : Drug Discovery World: Event highlights in 2024 so farShare: Drug Discovery World: Event highlights in 2024 so far
Pharma’s Almanac: Current Investment Trends in the Pharmaceutical Industry
Pharma’s Almanac
The surge in CAR-T and gene therapy approvals is driving pharma investment in cell therapy manufacturing. Josh Ludwig, ScaleReady's Global Director of Commercial Operations, discusses the success of therapies like Carvykti underscores the need for robust manufacturing. This growing demand will fuel further investment in both therapies and the supporting manufacturing technologies.
Read the article : Pharma’s Almanac: Current Investment Trends in the Pharmaceutical IndustryShare: Pharma’s Almanac: Current Investment Trends in the Pharmaceutical Industry
Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?
Pharma’s Almanac
Digital transformation in pharma needs careful planning, according to Josh Ludwig of ScaleReady. User-friendly technology and streamlined operations are key. Technology providers must partner with pharma companies to ensure successful implementation.
Read the article : Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?Share: Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?
